Macrogenics (MGNX) Revenue Growth (3y) (2015 - 2026)
Macrogenics (MGNX) Revenue Growth (3y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - | - |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 468.28 Bn | 463.49 Bn | 1.35 Bn | 50.07% |
| 5 | Vertex Pharmaceuticals | 122.49 Bn | 115.24 Bn | 2.59 Bn | 7.94% |
| 6 | Regeneron Pharmaceuticals | 70.26 Bn | 61.51 Bn | 3.31 Bn | 4.47% |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - | - |
| 8 | Argenx Se | 55.67 Bn | 50.48 Bn | 1.41 Bn | 79.44% |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn | 54.05% |
| 10 | Macrogenics | 248.09 Mn | 181.57 Mn | - | -5.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.34% |
| Dec 31, 2025 | -17.38% |
| Sep 30, 2025 | 20.40% |
| Jun 30, 2025 | -5.08% |
| Mar 31, 2025 | 5.92% |
| Dec 31, 2024 | 41.41% |
| Sep 30, 2024 | 91.92% |
| Jun 30, 2024 | -29.46% |
| Mar 31, 2024 | -18.60% |
| Dec 31, 2023 | -18.77% |
| Sep 30, 2023 | -17.11% |
| Jun 30, 2023 | -13.44% |
| Mar 31, 2023 | 82.96% |
| Dec 31, 2022 | 42.63% |
| Sep 30, 2022 | 30.59% |
| Jun 30, 2022 | 34.90% |
| Mar 31, 2022 | 4.74% |
| Dec 31, 2021 | -3.60% |
| Sep 30, 2021 | 36.93% |
| Jun 30, 2021 | 17.76% |